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raises two points.
First, that we cited a newspaper article interview with a
source who appears to have been an industry lawyer. On this
basis, we withdraw the paragraph in question.
Second, Dr. Revilla Beltri states that there are inaccuracies in
the published article with regard to the Mexican regulatory
framework surrounding biosimilars. We stand by our assertion
in the article that a new regulatory pathway had only been
recently created in Mexico to reﬂect the increasing number of
biosimilars coming into that market and at the time the article
was submitted for publication, that regulatory pathway was still
evolving. In fact, the October 2011 Decreto referenced in
Dr. Revilla Beltri’s letter speciﬁes that biosimilar regulation inMexico should be addressed by a subcommittee on a case-
by-case basis but did not specify the regulatory structure that
would surround such subcommittees. The second regulation
quoted by Dr. Revilla Beltri was enacted after our article was
accepted for publication.Erik Sandorff, MA, MBA
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